Capricor Therapeutics (CAPR) Non Operating Income (2010 - 2026)

Capricor Therapeutics' Non Operating Income history runs 17 years deep, the most recent figure standing at $2.8 million for Q1 2026.

• On a quarterly basis, Non Operating Income rose 378.82% year-over-year to $2.8 million in Q1 2026; TTM through Mar 2026 was $5.3 million, a 140.84% increase from a year earlier, with the FY2025 full-year figure at $3.1 million, up 47.77% from the prior year.
• Non Operating Income grew to $2.8 million in Q1 2026 per CAPR's latest filing, from -$1.0 million in the prior quarter.
• Across five years, Non Operating Income topped out at $2.8 million in Q1 2026 and bottomed at -$1.0 million in Q4 2025.
• The 5-year median for Non Operating Income is $471829.0 (2024), against an average of $617477.4.
• Across the five-year window, Non Operating Income jumped 2998.53% in 2023 and slumped 274.34% in 2025, its largest moves.
• Year by year, Non Operating Income stood at $345433.0 in 2022, then jumped by 50.3% to $519203.0 in 2023, then climbed by 11.95% to $581238.0 in 2024, then slumped by 274.34% to -$1.0 million in 2025, then soared by 379.43% to $2.8 million in 2026.
• Per Business Quant, the three latest CAPR Non Operating Income figures stand at $2.8 million (Q1 2026), -$1.0 million (Q4 2025), and $1.7 million (Q3 2025).